Dani Bancroft, Author at Labiotech.eu - Page 10 of 23

About

Former Editor, now flitting back and forth as a freelancer. Originally from London and studied Zoology at the University of Reading, UK. Previous work includes having written for The Spark University Newspaper and the Wellcome Trust.

Articles by Dani Bancroft

eduardo kac bioart alba gfp genesis synbio cypher edunia transArt

News and Trends 15 Jan 2016

Faces of BioArt: Eduardo Kac and His Transgenic Organisms

Last week I talked about my experience meeting Susanna Hertrich at the Art Laboratory Berlin, and now I move to Eduardo Kac, who actually coined the term ‘BioArt’. As a US-Brazilian from Rio, Eduardo has developed a global reputation as a ‘Transgenic Artist‘. One of Eduardo Kac‘s most famous pieces, ‘Genesis‘ (1999), was a transgenic […]

January 15, 2016 - 2 minutesmins - By Dani Bancroft

gals german life sciences startup accelerator sonormed tinnitracks ayoxxa personal medsystems pepperprint

News and Trends 15 Jan 2016

The German Accelerator in Boston’s 4 Rising Biotech Stars

During the 34th JP Morgan Healthcare Conference in San Francisco, the German Accelerator Life Sciences (GALS) announced the first four companies to participate in its Cambridge-based program. Germany has a long-standing reputation for life science innovation. However, most pharmaceutical and biotech companies are now headquartered in the US, and significantly more digital health solutions are […]

January 15, 2016 - 3 minutesmins - By Dani Bancroft

glycomar astaxanthin polysacchiride prasinotech mmicroa microalgae biotech algae

News and Trends 14 Jan 2016

World First: Scotland and Norway have Founded a Unique Oceanic Algae Plant

GlycoMar (Scotland) and MicroA (Norway) are Algae specialists in the Biotech industry which have now funded a joint Venture, Prasinotech, which is the first in the world to refine the production of polysaccharides from microalgae. GlycoMar is based at the European Centre for Marine Biotechnology, near Oban (Scotland), and is a specialist biotech developing new […]

January 14, 2016 - 3 minutesmins - By Dani Bancroft

HIV abivax Alexey Kashpersky abx464 trial antiviral

News and Trends 13 Jan 2016

A Phase II HIV Antiviral from France Has Promising Results

Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy for patients with HIV infection, which could potentially take a corner in an annual $18Bn market. HIV and AIDs have a long-standing history (the quick – yet fascinating story of which can be read here), and since 1983 (when the […]

January 13, 2016 - 3 minutesmins - By Dani Bancroft

cellectis ucart19 nature cancer car t cell leukemia crs cytokine

News and Trends 12 Jan 2016

Cellectis has Discovered an ‘On-Switch’ to Make CAR-T Safer and Better Controlled

Cellectis researchers have managed to come up with a new CAR architecture with a small-molecule triggered ‘on-switch’, permitting better control and safety in CAR T-cell therapy, as published in Nature. As we discussed during our interview with Andre Choulika, CEO of Cellectis, last month, one major drawback to CAR-T treatment for cancer is the lack of […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

clostridium difficile microbiomics seres health therapeutics nestle science crohns ibd uc cdi

News and Trends 12 Jan 2016

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Microbiomics is a hot area for biotech. Now US Seres Therapeutics and Nestlé Health Sciences have signed a massive drug development deal for bowel diseases and C.difficile infections. By correcting the fundamental microbiome dysbiosis that is the root cause of many diseases, Seres Theraputics in Cambridge (US) is creating a profoundly new and important way […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT

prostate cancer trod encage leuven ucl vesalius

News and Trends 11 Jan 2016

TROD’s MedTech for Prostate Cancer Kills Tumor Cells with Radio Waves

TROD Medical, the medical device company developing tools for focal ablation, today announced that it has received CE Mark Approval for its Encage device. Encage is a breakthrough in treatment for prostate cancer, one of the most common soft tissue cancers in the world with around 240,000 new cases every year in the US alone. […]

January 11, 2016 - 2 minutesmins - By Dani Bancroft

innate pharma immunooncology biotech cancer orega sanofi

News and Trends 11 Jan 2016

A French Biotech is Monopolising Immuno-Oncology with Big Euro Deals

Marseille’s Innate Pharma is building an Immuno-Oncology Monopoly, deal by deal. Selling to the French Pharma Giant, Sanofi, this 112 employee biotech has used their Sanofi-income to buy up Lyon-based Orega Biotech‘s checkpoint inhibitor program. Sanofi and Innate Pharma will work together on the generation and evaluation of up to two bispecific NK cell engagers, […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

Universal cancer diagnostic test illumina bill gates grail guardant health ngs

News and Trends 11 Jan 2016

How about the $100M Holy ‘GRAIL’ in Cancer Diagnostics? A Universal Test Start-up Faces German Competition

Illumina, the €22Bn Market cap NGS specialist, and Bill Gates pooled a $100M to fund the startup, ‘Grail’, which will be used to find a universal cancer detection test for Doctors. The startup will be based in San Francisco (US) with additional financial backing to include Bill Gates amongst others. The tests in question are […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

transgene pecvex oncolytic liver cancer lee pharma

News and Trends 11 Jan 2016

Transgene shares jump 50% in 2 days After Announcing Phase III Trial for Liver Cancer

This multinational Phase III Trial for an Oncolytic Immunotherapy for Advanced Liver Cancer could be what really defines French Transgene as the underdog which finally sprang to fame. Transgene, in Strasbourg, was founded in 1979, as France’s oldest Biotech (only 3 years after Genentech was born on the other side of the Atlantic). However, unlike Genentech, […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

biogen alzheimer proteros rodin therapeutics atlas neurology

News and Trends 8 Jan 2016

Epigenetics Baby of Proteros is Signing Up with Top US Neurology Specialists

Founded in just 2013 by German Proteros and the US Atlas Ventures, Rodin Therapeutics is working epigenetics into discovery of novel therapies for Neurological diseases. Now they have hooked one of the largest players in the field, Biogen, into a €446M partnership. Since its inception within Atlas Venture’s company-creating seed program in March 2013, Rodin […]

January 8, 2016 - 3 minutesmins - By Dani Bancroft

Jacobsons Exhibition view screen

News and Trends 8 Jan 2016

BioArt in Berlin: Making Dystopia Beautiful with Prostheses and the Transhuman Life

I met the curators of a BioArt Gallery in Berlin very recently and they invited me to their latest of exhibition ‘Prostheses: Transhuman Life’ by the Artist Susanna Hertrich. The exhibition, hosted by Christian De Lutz and Regine Rapp (the wonderfully warm curators of Art Laboratory Berlin) presented ‘wearable tech’ devices made to trigger emotions, […]

January 8, 2016 - 4 minutesmins - By Dani Bancroft

ADVERTISEMENT